Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: COVID-19, SARS-CoV2
Interventions: SAB-185, Normal saline; Biological · Other
Lead sponsor: SAb Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 3
States / cities: Wichita, Kansas • Syracuse, New York • San Antonio, Texas

Conditions: Healthy, Menopause
Interventions: Dietary Supplement with Proprietary Herbal Extract Blend and GABA, Placebo; Dietary Supplement · Other
Lead sponsor: Olly, PBC; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Volunteers
Interventions: selonabant, placebo; Drug
Lead sponsor: Anebulo Pharmaceuticals; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Adults, Elderly Subjects
Interventions: TD-1439, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Alzheimer's Disease
Interventions: AZD3293, Placebo, Moxifloxacin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: LJN452; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Orlando, Florida • Knoxville, Tennessee

Conditions: Healthy
Interventions: Tramadol HCl, Moxifloxacin 400 mg, Tramadol HCl Placebo, Moxifloxacin Placebo; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Bacterial Infections
Interventions: TP-271, Placebo; Drug
Lead sponsor: Tetraphase Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: Placebo, Oxycodone + Naltrexone, Oxycodone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Bleeding
Interventions: Andexanet alfa (Gen 1 Process 2), Apixaban 5 MG, Rivaroxaban 20 MG, Enoxaparin sodium, Edoxaban 60 MG, Andexanet alfa (Gen 2), Andexanet alfa (Gen 1 Process 3), Apixaban 10 MG, Rivaroxaban 10 MG; Biological · Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Cypress, California

Conditions: Psoriasis
Interventions: ABBV-553, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 4
States / cities: Anaheim, California • Toluca, California • Port Orange, Florida + 1 more

Conditions: Healthy
Interventions: Lamotrigine, BI 409306, Placebo, BI 425809; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Long Beach, California • Marlton, New Jersey

Conditions: Healthy Volunteer
Interventions: Not listed
Lead sponsor: Biogen; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 246 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 1 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GZR-18, Placebo; Drug · Other
Lead sponsor: Gan and Lee Pharmaceuticals, USA; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Dyslipidemia, Healthy Volunteers
Interventions: TAP311; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Healthy
Interventions: BIIB118; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obesity
Interventions: GSK2890457, Metformin, Placebo, Liraglutide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 3
States / cities: Chula Vista, California • Miami, Florida • Overland Park, Kansas

Conditions: Serious Gram-negative Infections
Interventions: Intravenous infusions of WCK 5222, Placebo; Drug
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Macular Degeneration
Interventions: pazopanib, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years to 64 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Volunteers
Interventions: E2511, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Type 2 Diabetes Mellitus
Interventions: BMF-219, Placebo; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 443 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 36
States / cities: Canoga Park, California • Fountain Valley, California • La Mesa, California + 28 more

Conditions: Healthy, Hepatic Impairment
Interventions: Selpercatinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Anaheim, California • Monterey Park, California • Tustin, California + 4 more

Conditions: Allergic Contact Dermatitis
Interventions: EB01 Cream Placebo, EB01 Cream 0.2%, EB01 Cream 1.0%, EB01 Cream 2.0%; Drug
Lead sponsor: Edesa Biotech Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 14
States / cities: Long Beach, California • Washington D.C., District of Columbia • Delray Beach, Florida + 11 more

Conditions: Degenerative Joint Disease, Control Subjects
Interventions: MRI, Magnetic Resonance Imaging; Diagnostic Test
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

One Week Clinical Study in Subjects With Menopausal Symptoms

I.V. Selonabant in Healthy Adult Subjects

Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects

AZD3293 Thorough QT Study in Healthy Male Volunteers

Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects

Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants

A Phase 1 Safety and PK Study of IV TP-271

A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis

A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine

MS PATHS Normative Sub-Study

Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)

To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes

MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers

A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers

A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants

Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis

MRI of the TMJ in Patients With DJD